alexa The Effect of Metformin on Colorectal Carcinoma in Type 2 Diabetes Mellitus Patients: A Markov Model Analysis | Open Access Journals
ISSN: 2167-7700
Chemotherapy: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

The Effect of Metformin on Colorectal Carcinoma in Type 2 Diabetes Mellitus Patients: A Markov Model Analysis

Tianhong Su1, Yihao Liu2, Weifeng Liu3, Shuling Chen4, Qian Zhou5, Zhenwei Peng5, Sui Peng1,5* and Haipeng Xiao2*

1Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, PR China

2Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, PR China

3Department of Anesthesiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, PR China

4Division of Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, PR China

5Clinical Trial Unit, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, PR China

*Corresponding Authors:
Sui Peng
Department of Gastroenterology and Hepatology
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, PR China
Tel: +86-20-87755766
E-mail: pengsui2002@vip.sina.com
 
Haipeng Xiao
Department of Endocrinology
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, PR China
Tel: +86-20-87755766
E-mail: xiaohp@mail.sysu.edu.cn

Received date: March 18, 2017; Accepted date: May 22, 2017; Published date: May 29, 2017

Citation: Su T, Liu Y, Liu W, Chen S, Zhou Q, et al. (2017) The Effect of Metformin on Colorectal Carcinoma in Type 2 Diabetes Mellitus Patients: A Markov Model Analysis. Chemotherapy 6:233. doi: 10.4172/2167-7700.1000233

Copyright: © 2017 Su T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Chemotherapy: Open Access

Abstract

Objective: Morbidity and mortality of colorectal cancer (CRC) in type 2 diabetes mellitus (T2DM) patients are higher than that of general population, the mechanism of which remains undetermined. Some studies found that metformin could lower the risk of cancer, including CRC, in T2DM patients, but others demonstrated different results. Therefore, we target to evaluate the CRC prevention effect of metformin in comparison with that of other T2DM medications from a Markov model perspective.

Methods: A Markov model simulating a randomized trial comparing metformin with non-metformin treatment in T2DM patients without CRC over 11-year time horizon was constructed based on data from 8 literatures. CRC morbidity was selected as endpoint. Monte Carlo analysis with 10,000 patients allocated for each arm was performed to assess CRC morbidity and cumulative tumor-free survival in each group.

Results: In contrast with non-metformin group, T2DM patients treated with metformin had a lower rate of CRC (1.670% vs. 2.146%). Moreover, cumulative tumor-free survival of metformin group was, slightly but significantly, better than that of non-metformin group (10.91 years vs. 10.88 years, p<0.001). Monte Carlo Strategy Selection analysis showed that metformin group had a better optimal frequency than the other one.

Conclusion: T2DM patients treated with meformin have a lower morbidity of CRC and a better cumulative tumorfree survival than that of the non-metformin group. Large scale, randomized, double blind clinical trials are needed to illustrate the role of metformin in the prevention of CRC.

Keywords

Colorectal carcinoma; Type 2 diabetes mellitus; Metformin; Non-metformin medications; Morbidity; Cumulative tumor-free survival; Markov model

Introduction

Colorectal carcinoma (CRC) is the third most common cancer and the third leading cause of cancer death in America. Adoption of colonoscopy screening and new treatments declined the rate by 3.9% per year among adults aged 50 years and older in the USA. However, the incidence in America increased by 1.1% per year among men and women aged younger than 50 years, in which the increased prevalence in obesity prevalence and the emergence of unfavorable dietary patterns have been implicated [1]. While in Asia-Pacific region, CRC incidence has increased since the last decades and is the third most prevalent cancers, which is also attributed to such environmental factors as obesity and the adoption of the Western lifestyle [2].

Many researches demonstrate that Western dietary habits and increasing incidence of metabolic syndrome result in more and more CRC cases [3,4]. Morbidity and mortality of CRC in type 2 diabetes mellitus (T2DM) patients are higher than that in the general population [5], since they have such risk factors in common as obesity, alcohol consumption and Western diet pattern and so on [6]. On exploring chemopreventive drugs against cancer, many studies, but not all, found that metformin, the typical first-line treatment for T2DM, reduced the incidence of many cancers, including CRC [7,8]. Nevertheless, some studies illustrated that metformin provided no protective effect against cancers, including CRC in T2DM patients [9,10]. Therefore, the role of metformin on CRC remains obscure and large scale, randomized, controlled trials (RCTs) are needed to unveil their relationship.

Nevertheless, it is difficult to conduct those large trials due to tremendous difficulties in patient enrollment and treatment allocations. By emulating disease process where patients progress through different health states over the preset cycles, Markov model can be applied to assess disease’s outcomes. Generally, Markov models are applied in describing stochastic processes, which are random processes evolving over time [11]. Since its first introduction in predicting medical prognosis in 1983, Markov models have been more and more prevalent in the field of clinical evaluations [12]. By dividing a disease into distinct states and assigning transitions probabilities for movement between those states, then attaching estimates of costs and health outcomes to the states and running the model over many cycles, the model is able to estimate the long-term costs and outcomes associated with that disease and the related healthcare interventions [11]. The advantage of Markov model by taking into accounts both costs and outcomes over a period of time makes it particularly suitable to model the progression of chronic disease. Up to date, Markov model has been widely adopted in the evaluation of disease screening or treatments around the world [13-15]. It has been successfully used in the simulation of head–to– head comparison of the treatment efficacy of two modalities [16,17]. Therefore, we attempted to simulate a RCT which compared metformin with non-metformin treatment in terms of CRC incidence for T2DM patients without CRC by building a Markov model.

Methods and Materials

Model construction

A multi-state Markov analyzing model, which emulated a RCT with a follow-up period of 11 years, was constructed to compare the CRC prophylaxis effect of metformin with that of other T2DM medications in T2DM patients. Thus, in this model, the two therapeutic decisions to be analyzed were metformin and other antidiabetic agents. The end point was defined as CRC morbidity. Diagram of this model was represented in Figure 1. As was showed in this model, a total of 6 Markov states were developed including three states in metformin group and the remaining in another group. The cycle length was set to be one year, which was the pertinent interval to observe the treatment response of tumor episodes. Further, in consideration of obtaining sustained outcomes and the actual life expectancy of T2DM patients, we assumed the patients to be observed for 11 years [18]. Then, the half-cycle correction was used [19]. The annual mortality or morbidity was derived from the median survival or cumulative probability of survival using the declining exponential approximation of life expectancy (DEALE) method [20]. The TreeAge-Pro-2008 software (TreeAge Software Inc., Williamstown, MA, USA) was applied to build up such a Markov model.

chemotherapy-Flow-diagram

Figure 1: Flow diagram of Markov analyzing model. Each pane represents a health State; Straight lines with arrows indicate transition from one state to another one while circular arrows suggest that some patients may stay at the same state for more than one cycle. Two therapy strategies were compared in this model with initial treatments being metformin and non-metformin medications.

Furthermore, sensitivity analyses were also performed to evaluate the contribution of certain variable to the CRC morbidity and the robustness of our results [21]. One-way and two-way sensitivity analysis was performed to assess the extent to which an endpoint was influenced by respectively changing the value of one and two estimates with the other parameters remaining constant. Last, a second-order Monte Carlo probabilistic sensitivity analysis was performed to evaluate the total impact of parameter uncertainties on the model results, with 10,000 patients allocated into each group respectively.

Literature selection

Transition probabilities between each state in this model were extracted from the included literatures published in English that investigated the therapeutic efficacy of metformin and/or other T2DM medications on CRC for T2DM patients without CRC (Table 1) [18,22-30]. Literatures were retrieved from two databases of PubMed and Cochrane Library with the latest searching on September 27, 2016. The following search terms were used: colorectal carcinoma, colorectal cancer, colorectal malignancies, CRC, metformin, type 2 diabetes mellitus, T2DM, morbidity, prevalence, mortality, death. Reference lists of the included studies were hand-searched to identify further relevant trials. If more than one article was published in the same data subset, only the most recent article was employed. Besides, two investigators independently searched all the eligible studies and a third party was consulted when the two searchers’ opinions differed. Studies were to be recruited if they met the following criteria:

Author Sample size Age Region Ma users NMb
users
CRCc cases
M users NM users
Meei-Shyuan Lee [22] 480, 984 >20 Taiwan 11,221 4213 30 26
Home [23] 4351 60 (mean) UK 1454 2897 7 14
Rikje Rutter [24] 85, 289 >18 Netherlands 52,698 32,591 228 299
Bernd Kowall [25] 60571
(UK);
19692
(GER)
30-89 German and UK 55,988 17,704 281 150
Ramjeesingh [26] 277 24-98 Canada 133 144 133 144
Jin Ha Lee [27] 595 30-88 Korea 258 337 258 337
Ming Chia Hsieh [28] 61777 61.44 ±
13.23 (mean)
Taiwan 3963 6823 46 163

Table 1: Detailed characteristics of studies included in this model. A: Metformin; B: Non metformin (other diabetic medications); C: Colorectal carcinoma.

(i) The entire population or subpopulation were adult patients with T2DM but without CRC.

(ii) Any of the parameter estimates applied in our model was reported.

(iii) RCTs, quasi-randomized trials, prospective or retrospective cohort studies were included whereas reviews, letters, case reports, editorials or comments and meeting abstracts were excluded.

Parameter estimation

Before pooling the extracted transition probabilities, double arcsine transformations on them were performed for variances stabilization [31]. The Wilson score method was also used to estimate the 95% confidence intervals (CIs) of these probabilities [32]. Then, STATA software (Stata Corp., College Station, TX, USA) was applied to pool the above mentioned rates using random-effect model. Further, SAS 9.2 (SAS Institute Inc., Cary, NC, USA) was employed to apply the Wilson score method and calculate the 95% CIs.

Summary of transition probabilities and assumptions

The transition probabilities retrieved from the literatures were summarized in Table 2. For T2DM patients without CRC, the estimated annual mortality was derived by excluding CRC-specified mortality from that of the whole T2DM population [33]. The average age of patients in the included studies ranged from 25 years to 79 years, then we assumed the mean age of this cohort to be 60–65 years with the annual age-related mortality being 0.055 [34].

Variable Metformin Non-metformin
Annual mortality rate of general population(60-65 years old) 5.5% [33]
Mortality of T2DMa patients without CRCb 0.154 [24]
CRC morbidity 0.153% (0.068%-0.201%) [22-25,28] 0.197% (0.197%-0.242) [22,24,28]
CRC specific mortality 5% (1.56%-10.248%) [26,27,33] 11.3% (4.21%-18.82%) [26,27,33]
Non-CRC mortality 1.3% (0.335%-2.667%) [29,30] 3.3% (2.536%-4.397%) [26,33]

Table 2: Estimated transition probabilities extracted from literatures for the Markov Model. a: Type 2 diabetes mellitus; b: Colorectal carcinoma.

Results

Morbidity and cumulative tumor-free survival outcome of the model

Based on the data from literature review, the CRC morbidity of metformin group and non-metformin group were 1.670% and 2.146% respectively (Figure 2). The expected cumulative tumor-free survivals were 10.908 years and 10.882 years for metformin and non-metformin groups, respectively (p<0.001, Figure 3).

chemotherapy-CRC-morbidity

Figure 2: CRC morbidity curves for metformin and non-metformin groups in the treatment of T2DM patients. The CRC morbidity of metformin group was lower than that of non-metformin group.

chemotherapy-Cumulative-tumor

Figure 3: Cumulative tumor-free survival curves for metformin and nonmetformin groups in the treatment of T2DM. Curves of metformin group showed a better result than that of non-metformin group.

One-way and two-way sensitivity analysis

One-way sensitivity analyses for all the variables demonstrated that the curves of expected cumulative tumor-free survival representing metformin treatment were always above those representing non-metformin until the CRC morbidity of metformin group was higher than 0.197%, which suggested that metformin treatment had better tumor-free survival benefit than non-metformin therapy in most cases (Figure 4). Similar result could be observed in two-way sensitivity analysis (Figure 5). For any of the two variables, there was no point of intersection between these two therapies as showed in the Figure even when comparing the most sensitive factors in both groups and assuming the best scenario for non-metformin treatment.

chemotherapy-One-way-sensitivity

Figure 4: One-way sensitivity analysis for CRC morbidity. The effects of CRC rate on cumulative tumor-free survival for metformin group and non-metformin group were analysed. Note the incremental difference between these two groups.MNCRC to CRC: CRC morbidity of CRC-free T2DM patients in metformin group.

chemotherapy-Two-way-sensitivity

Figure 5: Two-way sensitivity analysis for CRC rate in each group. Whichever scenario it was, metformin treatment was always the optimal decision.
MNCRC to CRC: CRC morbidity of CRC-free T2DM patients in metformin group.
NMNCRC to CRC: CRC morbidity of CRC-free T2DM patients in non-metformin Group.

Second-order Monte carlo simulation

The probability distributions of cumulative tumor-free survival using Monte Carlo Simulation demonstrated that the estimated CRCfree survival in metformin group (95% CI: 10.906–10.908 years) was better than that in non-metformin group (95% CI: 10.881–10.882 years) (Figures 6A and 6B). The 95% CIs of the difference in overall survival between these two groups were 0.0258-0.0264 years. The difference was statistically significant (p<0.001). This result further validated our model by suggesting that the superiority of metformin to non-metformin would not be altered by the uncertainties of parametric estimations.

chemotherapy-second-order

Figure 6: The second-order Monte Carlo probability distribution of the cumulative tumor-free survival (EV) in strategy 1 (metformin group) (A) and strategy 2 (nonmetformin group) (B). Note that the difference of distribution between these two therapy strategies was significant.

Discussion

Anti-malignancies effect of metformin is not well determined. Some previous observational and mechanistic studies show positive results [35-37]. However, no demonstrable protective effect of metformin against malignancy is shown in the RCT (OR=0.69, 95% CI: 0.26–1.82) [23]. Yet, this may be due to the fact that these two RCTs and others were not primarily launched to collect data on CRC and the numbers of malignancy cases are small, in the case of which bases could be expected. By simulating RCT, Markov model can be applied to predict disease outcomes, compare treatment efficacy of various therapies and evaluate the cost-effectiveness of treatment modalities [38,39]. Thus, it may help to provide informative data in the comparison of metformin and other anti-diabetes medications for the prevention of CRC in T2DM patients when RCTs are unavailable.

Based on 7 observational and 1 RCT researches recruited in this study, we constructed a Markov model to simulate a RCT analyzing the CRC prophylaxis effect of metformin in CRC-free T2DM patients and found that metformin, in comparison with other diabetes medications, had a lower risk of CRC. This finding is in accordance with the results of some previous observational studies and meta-analysis [38,39]. A growing body of evidence could back up the protective effect against CRC of metformin from in vivo and in vitro studies. More and more studies demonstrate a systemic and cellular-targeted effect by which metformin suppresses carcinogenesis. Systemic (insulin-dependent) effect of metformin can indirectly suppress tumorigenesis by improving hyperglycemia to neutralize the Warburg effect, which characterizes the metabolic feature of cancer cells through facilitating bypass senescence [40,41]. While targeting at cancer cells, metformin can directly exert pleiotropic inhibitory effects on various signalings involved in the process of survival and metastasis [42], including mTOR pathway, which plays a key role in proliferation and carcinogenesis in various cancers [43]. Furthermore, metformin can regulate the number and/ or the maintenance of cancer stem cells by down regulating systemic metabolic markers including IGF-1 and insulin, which is essential for the generation and/or maintenance of mammal stem cells [44-46]. Anticancer effect of metformin also works in animal model. Zaafar DK et al. found that metformin protected against DMH-induced colon cancer in non-diabetic and diabetic mice, the therapeutic effect of which may be, at least in part, attributed to its anti-angiogenic and anti-proliferative mechanisms [47]. Abovementioned evidence from in vivo and in vitro supports the protective effect of metformin as one of the promising candidates for cancer therapeutics. Further, our model presented, slightly but significantly, an encouraging cumulative tumor-free survival outcome for patients treated with metformin. This may be due to the fact that the Markov cycle was set to repeat 11 times, which ensured a long enough follow-up period to obtain data from patients as much as possible. However, the effect of metformin on CRC survival warrants further demonstration by RCTs which stratify CRC patients. The process of CRC progression and its various corresponding therapy regimen need to be taken into account, because these variables could also impact patients’ survival benefit, which may bias the effect of metformin and other diabetes medications.

Limitations of this study were demonstrated as follow. Firstly, the non-metformin group consisted of multiple treatment regimens, including the mono-application or combination of rosiglitazone, glibenclamide, sulfonylurea and insulin and so on. This would inevitably cause biases. Then, limited information about the survival benefit generated by metformin on CRC patients could be attained. Secondly, in spite of detailed systematic review of all the eligible RCTs and observational studies were performed to retrieve data as accurate as possible, the paucity of RCTs included might influence the results to some extent. Moreover, our pooled parameters were based on data from observational studies, while just one RCT is applicable. It is acknowledged that observational studies had such methodical drawbacks as a tendency to time-related biases, including immortal time bias and time-lagging issues. Thirdly, covariates of included studies were incomplete and inconsistent even after statistical adjustment. Finally, literatures pooled were confined to English language researches, which might potentially evoke publication bias. Notwithstanding, it is impractical to expect a model simulating exactly the real clinical scenario because of too many uncertainties regarding the treatment selection during a patient’s whole disease course. Our model is a simplified, practical mathematical model aiming to provide some insight for these controversial research hotspots, but not to replace RCTs completely.

Therefore, based on this Markov model with enormous sample size and long follow-up period, our findings may help the future investigations and management of T2DM with regards of CRC. Validation for our findings will merit further high-quality studies.

Acknowledgement

The manuscript does not contain clinical studies or patient data. For this type of study formal consent is not required. This article does not contain any studies with human participants or animals performed by any of the authors. The authors declare that they have no conflict of interest.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 82
  • [From(publication date):
    June-2017 - Jun 23, 2017]
  • Breakdown by view type
  • HTML page views : 65
  • PDF downloads :17
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsonline.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsonline.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsonline.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsonline.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsonline.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsonline.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsonline.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsonline.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version